News | Digital Pathology | January 25, 2019

New Pathology Guideline Advances Accuracy in Breast Cancer Testing

Evidence-based guideline from College of American Pathologists helps labs use quantitative image analysis in HER2 immunohistochemistry testing

New Pathology Guideline Advances Accuracy in Breast Cancer Testing

January 25, 2019 — The College of American Pathologists (CAP) published the first-ever evidence-based clinical practice guideline to help laboratories use quantitative image analysis (QIA) in HER2 immunohistochemistry (IHC) testing for breast cancer. The guideline was published in an early online edition of the Archives of Pathology & Laboratory Medicine.1

QIA is the computer algorithm-assisted detection of specific features in an image following the digitalization of a glass slide image. Advancements in genomics, computing and imaging technology are spurring new opportunities to use QIA for diagnostic testing.  And while it has been shown to improve consistency and accuracy of interpretation compared to manual scoring by pathologists, the lack of a clinical guideline has been a barrier to wider QIA adoption.

"We set out to bridge the gap between technology and clinical practice with recommendations based on expert review of published literature," said project chair Marilyn M. Bui, M.D., Ph.D., FCAP, of the Moffitt Cancer Center, Tampa, Fla. "The recommendations will aid laboratories to ensure that diagnoses are accurate and consistent, which is essential to each patient's prognosis and treatment planning."

To develop the guideline, the CAP convened an expert panel of pathologists and histotechnologists with expertise in digital pathology, immunohistochemistry, quality management and breast pathology. The panel systematically reviewed more than 250 relevant articles and relied on evidence from more than 65 to develop the guideline's 11 recommendations. The guideline development process also included an open public comment period to include comments from professional associations and individuals, feedback from the guideline advisory panel, and independent peer review from a panel of CAP members.

Notably, the guideline recommends steps to validate QIA before implementing it, and steps for ongoing maintenance and evaluation so that quality is controlled and assured. Additionally, it recommends that laboratories should validate their QIA results for clinical use by comparing them to an alternative, validated method(s) such as HER2 in-situ hybridization methods or consensus images for HER2 IHC. The American Society for Clinical Pathology (ASCP) has endorsed the guideline through informed consideration by the ASCP Commission on Science, Technology & Policy.

The guideline is available at no charge on cap.org. Additional resources including an instructional presentation and summary of the recommendations are also available.

For more information: www.cap.org

Related Digital Pathology Content

Roche Launches uPath Enterprise Digital Pathology Software

Reference

1. Bui M.M., Riben M.W., Allison K.H., et al. Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer. Archives of Pathology & Laboratory Medicine. doi: 10.5858/arpa.2018-0378-CP

Related Content

Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...
Numerical simulation with a heterogeneous mouse

Numerical simulation with a heterogeneous mouse. (a) The geometry of the mouse with major organs near the source, and (b) the surface fluence computed with TIM-OS. Image courtesy of Rensselaer Polytechnic Institute.

News | Oncology Diagnostics | September 20, 2019
If researchers could observe drug delivery and its effect on cancer cells in real time, they would be able to tailor...
Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images

A smart algorithm has been trained on a neural network to recognize the appearance of breast cancer in MR images. The algorithm, described at the SBI/ACR Breast Imaging Symposium, used deep learning, a form of machine learning, which is a type of artificial intelligence. Image courtesy of Sarah Eskreis-Winkler, M.D.

Feature | Society of Breast Imaging (SBI) | September 06, 2019 | By Greg Freiherr
The use of smart algorithms has the potential to make healthcare more efficient.
Philips and Fujifilm booths at SIIM 2019.

Philips and Fujifilm booths at SIIM 2019.

Feature | SIIM | September 06, 2019 | By Greg Freiherr
Pragmatism from cybersecurity to enterprise imaging was in vogue at the 2019 meeting of the Society of Imaging Inform
Xifin Launches Version 6 of Laboratory Information System
News | Digital Pathology | September 05, 2019
Xifin announced the launch of the next evolution of its laboratory information system (LIS), Xifin LIS 6. The expanded...
Heath information technology diagram showing use of cloud storage.
Feature | Archive Cloud Storage | September 04, 2019 | Tyna Callahan
In healthcare, critical systems are being used to deliver vital information and services 24x7x365.
Global Diagnostics Australia Incorporates AI Into Radiology Applications
News | Artificial Intelligence | September 04, 2019
Global Diagnostics Australia (GDA), a subsidiary of the Integral Diagnostics Group (IDX), has adopted artificial...